The lawsuit, filed in the wake of concerns surrounding the drug Deramiocel, centers on allegations that Capricor violated the Securities Exchange Act of 1934. According to the complaint, the company modified its statistical analysis plan for clinical data without prior FDA agreement before resubmitting its Biologics License Application. This move reportedly masked significant risks regarding the lack of evidence for the drug's effectiveness.
Investors Eye Class Action Against Capricor Therapeutics Over BLA Issues
Investors who purchased Capricor Therapeutics shares between December 17, 2025, and July 26, 2026, face a critical deadline as Schall, Brown & Schwartz LLP organizes a securities fraud class action. The firm is seeking lead plaintiffs to address allegations that the company misled the market regarding its clinical data procedures.
As the market processed these disclosures, investors sustained losses, prompting the current litigation efforts. Brian Schall and David Schwartz of the Los Angeles-based firm are inviting affected shareholders to discuss their legal standing and potential recovery options. While the class has not yet been certified, interested parties must act before the September 28, 2026, deadline to seek a lead plaintiff role.
Comments (0)
No comments yet. Be the first!